Press Releases

ABBOTT PARK, Ill., Sept. 25, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug Administration (FDA). As one of the most researched troponin diagnostic tests, doctors in the U.S. can now utilize this proven technology to help detect heart attacks faster and more accurately than con

PORTLAND, Ore., Sept. 25, 2019 /PRNewswire/ -- The CHP Group (CHP), the recognized leader and partner of choice in integrative healthcare, announces the release of the 2018 Patient Satisfaction Survey results. This survey – in its 18th year – is of seminal importance in understanding patient use, attitudes, and outcomes regarding integrative health

SAN FRANCISCO and HERZLIYA, Israel, Sept. 25, 2019 /PRNewswire/ -- 89bio, Inc. (89bio or the company), a clinical-stage biopharmaceutical company, has initiated dosing in its proof of concept Phase 1b/2a clinical trial evaluating its product candidate, BIO89-100, in patients with nonalcoholic steatohepat

PHILADELPHIA, Sept. 25, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the pricing of $75 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act

SAN FRANCISCO, Sept. 25, 2019 /PRNewswire/ -- JUUL Labs announced today that K.C. Crosthwaite will be joining the company as CEO effective immediately. The announcement from co-founders James Monsees, Adam Bowen and Kevin Burns follows Burns' decision to step down. In

CHARLOTTESVILLE, Va., Sept. 25, 2019 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held biotechnology company focused on discovering and developing drugs for metabolic disorders, has appointed Brian A. Johns, PhD, as Chief Scientific Officer. Dr. Johns joins the company following a prolific 20-year career with GSK, where he

LOS ANGELES, Sept. 25, 2019 /PRNewswire/ -- ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UA

SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will deliver a corporate presentation at the 2019 Cantor Global Healthcare Conference, being held

WASHINGTON, Sept. 25, 2019 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) is pleased to announce that its national stakeholder conference, 

NEWARK, Calif., Sept. 25, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the Cantor Global Healthcare Conference in New York.